Research programme: human monoclonal antibodies - MorphoSys/Pfizer

Drug Profile

Research programme: human monoclonal antibodies - MorphoSys/Pfizer

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys; Pfizer
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Undefined in Germany (Parenteral)
  • 31 Jan 2011 MorphoSys reaches a milestone in connection with an IND filing and initiation of a phase I trial of an antibody therapeutic in the area of oncology
  • 20 Dec 2006 MorphoSys and Pfizer have expanded their collaboration on the development of therapeutic antibodies until 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top